Multibagger Update: This micro-cap pharma stock hit an all-time high!

Over the last 1 year and year to date, the stock has gained 156.59 per cent and 50.26 per cent, respectively

Shares of Fredun Pharmaceuticals are on a phenomenal roll. A solid price volume break out was witnessed in the counter today.  

The scrip has rallied 4.40 per cent during early market hours to record a fresh 52-week high of Rs 1,355 on BSE today. Over the last 1 year and year to date, the stock has gained 156.59 per cent and 50.26 per cent, respectively.  

Fredun Pharmaceuticals Limited is engaged in manufacturing of various pharmaceutical formulations for pharma companies in India and across Africa, South-East Asia and CIS countries and Latin America. It is also in the business of healthcare and aims to be a holistic healthcare provider.

The company primarily offers various generic pharma products across various therapeutic segments such as anti-bacterial, anti-malarial, anti-fungal, cardiovascular, nephrology, dietary supplements, etc.

The company aims to focus on increasing business productivity through digital and non-digital initiatives along with system-oriented operations as they gradually transform from a B2B to a B2C Company. With a large part of capex undertaken in the last few years and operating at utilization of over 60 per cent, they aim to replicate the existing product portfolio through cost optimization and operating leverage.  

This is expected to further ensure incremental growth with minimal spends which shall aid margins and return ratios. In-line with the efforts, revenues are expected  to grow at 25-27 per cent in FY2023. 

Watch out for this trending micro-cap pharma stock in the coming sessions!